Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Efficacy of OPC-167832 in Pulmonary Tuberculosis
NCT03678688Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2018
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of quabodepistat in pulmonary tuberculosis (TB), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Early Bactericidal Activity at Day 14, Maximum Plasma Concentration at Day 14 and 6 more. Started Oct 2018; status: completed.
02
Drugs
quabodepistat
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT03678688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678688.